Hims & Hers Health (NYSE:HIMS) Stock Price Down 3.1% – Time to Sell?

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) fell 3.1% during trading on Wednesday . The company traded as low as $37.42 and last traded at $39.22. 8,825,124 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 12,917,730 shares. The stock had previously closed at $40.49.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on HIMS shares. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Citigroup reaffirmed a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a research report on Thursday. Leerink Partners boosted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and an average price target of $37.23.

Hims & Hers Health Stock Up 4.7 %

The business’s 50 day moving average is $37.45 and its 200-day moving average is $27.31. The firm has a market capitalization of $8.00 billion, a P/E ratio of 81.85 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,152 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the sale, the insider now owns 157,345 shares in the company, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $32.25, for a total transaction of $234,102.75. Following the completion of the sale, the insider now directly owns 184,947 shares in the company, valued at approximately $5,964,540.75. This represents a 3.78 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,062,011 shares of company stock valued at $36,892,724. Corporate insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently modified their holdings of the stock. SlateStone Wealth LLC increased its position in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after buying an additional 413 shares during the last quarter. Blume Capital Management Inc. raised its stake in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the period. Summit Investment Advisors Inc. lifted its holdings in Hims & Hers Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock valued at $480,000 after purchasing an additional 628 shares during the last quarter. Cim LLC boosted its position in Hims & Hers Health by 1.0% during the fourth quarter. Cim LLC now owns 71,869 shares of the company’s stock worth $1,738,000 after purchasing an additional 694 shares during the period. Finally, Quest Partners LLC increased its stake in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.